Kill Cliff adds Ignite, redesigns line of performance drinks
Performance beverage maker Kill Cliff has expanded its product line alongside a redesign. The Atlanta-based company, created by a former Navy SEAL, added Ignite to its lineup. It joins the freshly redesigned Endure and Recover products.
Ignite, which retails in a 12-oz. can, is designed to offer clean energy and hydration using natural caffeine, B vitamins and electrolytes, the company said. Endure, which sells in 16-oz. bottles, is designed to offer hydration and endurance using a blend of slow release low-glycemic carb fuel from sugar beets called Palatinose. Kill Cliff’s recover is designed to support hydration and recovery post-workout through a blend of plant extracts, B vitamins and electrolytes, the company said.
“We’ve designed this new full system of clean beverages to support the everyday warrior in all of us,” said Kill Cliff CEO Joe Driscoll. “Whether you’re training solo for an Iron Man, enjoying a killer group fitness class, or partnering with your little one in a pre-K 5k, we’re proud to offer products that fuel your mind and body.”
The launch and redesign are being supported by Kill Cliff’s Ignite Your Summer tour, which will hit six cities with activities that include fitness events, product sampling, workout videos and a sweepstakes.
The full line of Kill Cliff products are available in retailers nationwide, including military bases and all Hy-Vee stores and military bases, the company said.
Funding round brings higi $21M, new investors
Population health enablement company higi has completed a fundraising round that brought the company $21.3 million, led by such new investors as Flare Capital Partners and 7wireVentures. Higi said it would focus its new resources on expanding access points to its health monitoring stations, broaden engagement and bring population health workflow insights to bear on prevention and value-based outcomes.
Currently, higi has more than 11,000 smart health stations that enable consumers to create and build a longitudinal health profile and connect it to 80 health devices and applications, as well as their electronic health records.
“Building on their vast reach and established partnerships, higi is uniquely positioned to enable healthcare organizations improve risk stratification of their patient population and deepen their understanding of people’s health needs in real time – leading to prevention, early intervention and better care at lower costs,” Flare Capital Partners’ Michael Greeley said. “This investment will accelerate the company’s growth, and provide the leverage needed to continue building deeper data-driven solutions that can truly close gaps in care.”
As health care shifts to where it’s delivered — with retail becoming the frontline health-and-wellness marketplace, higi said it is hoping to accelerate this shift and serve as a “digital connective tissue” to help track and manage their health data.
“We are pleased to have raised over $21 million during this round. The significant investor interest reinforces higi’s unique position to connect consumers with payers and providers to deliver the services they need,” said higi CEO Jeff Bennett. “As retailers continue to bring healthcare solutions into their storefronts and consumers are looking for more effective means to manage their health, higi is forging this path by providing convenient and free ways to measure, connect, and act on health information.”
Study: Probiotics may help with bone density
A new study published in the Journal of Internal Medicine is highlighting a potential connection between the gut and bone density in older women. Though only covering 90 women, only 70 of whom completed it, the study found that the probiotic L. reuteri reduced bone density loss compared with the placebo.
“Previous studies in rodents have suggested that treatment with specific bacterial strains can improve bone density, but the present study demonstrates for the first time that this may also be the case in humans,” the researchers wrote, while acknowledging that their trial mostly functions as a proof-of-concept and a push for more, similar trials.
The study notes that data from 2005 showed that fractures related to osteoporosis, which is partly characterized by a loss of bone density, numbered more than 2 million and cost roughly $17 billion.